Institute Jules Bordet

Brussels 1000

1 studies enrolling now · 8 studies all time

What they study most

AML, Clear Cell Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, KRAS p, G12c Mutated /Advanced Metastatic NSCLC, MDS, Metastatic gpNMB Over-expressing Triple Negative Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Pancreatic Cancer, Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Solid Tumor

Studies at this site

• Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors — Recruiting now
• Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). — Completed
• A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors — Stopped early
• 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study — Completed
• DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 — Completed
• A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma — Stopped early
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed
• OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. — Completed